Management of vernal keratoconjunctivitis : Navigating a changing treatment landscape
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
Vernal keratoconjunctivitis (VKC) is a chronic, progressive, and potentially sight-threatening form of ocular inflammatory disease that primarily affects children and young adults. Prevalence varies by region, ranging from <2 per 10,000 in the United States to as high as 1,100 per 10,000 in parts of Africa. The rarity of VKC in developed countries can make differential diagnosis challenging, and treatment is often delayed until the disease is advanced, and symptoms are significantly impacting patients' quality of life. Although once viewed primarily as an immunoglobulin E-mediated condition, approximately 50% of patients with VKC do not exhibit allergic sensitization. It is now recognized that the immunopathology of VKC involves multiple inflammatory pathways that lead to the signs, symptoms, and conjunctival eosinophilic and fibroproliferative lesions that are a hallmark of the disease. We examine the evolution of our understanding of the immunopathology of VKC, the expanding VKC treatment armamentarium, the clinical implications of emerging treatment approaches, and future directions for VKC research and practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Survey of ophthalmology - 69(2024), 2 vom: 25. März, Seite 265-278 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ali, Asim [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
83HN0GTJ6D |
|---|
| Anmerkungen: |
Date Completed 29.03.2024 Date Revised 29.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.survophthal.2023.10.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363827374 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363827374 | ||
| 003 | DE-627 | ||
| 005 | 20240330000517.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.survophthal.2023.10.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1355.xml |
| 035 | |a (DE-627)NLM363827374 | ||
| 035 | |a (NLM)37890678 | ||
| 035 | |a (PII)S0039-6257(23)00138-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ali, Asim |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of vernal keratoconjunctivitis |b Navigating a changing treatment landscape |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Vernal keratoconjunctivitis (VKC) is a chronic, progressive, and potentially sight-threatening form of ocular inflammatory disease that primarily affects children and young adults. Prevalence varies by region, ranging from <2 per 10,000 in the United States to as high as 1,100 per 10,000 in parts of Africa. The rarity of VKC in developed countries can make differential diagnosis challenging, and treatment is often delayed until the disease is advanced, and symptoms are significantly impacting patients' quality of life. Although once viewed primarily as an immunoglobulin E-mediated condition, approximately 50% of patients with VKC do not exhibit allergic sensitization. It is now recognized that the immunopathology of VKC involves multiple inflammatory pathways that lead to the signs, symptoms, and conjunctival eosinophilic and fibroproliferative lesions that are a hallmark of the disease. We examine the evolution of our understanding of the immunopathology of VKC, the expanding VKC treatment armamentarium, the clinical implications of emerging treatment approaches, and future directions for VKC research and practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Corticosteroid | |
| 650 | 4 | |a Cyclosporine | |
| 650 | 4 | |a Dupilumab | |
| 650 | 4 | |a Eosinophil | |
| 650 | 4 | |a Immune | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Montelukast | |
| 650 | 4 | |a Omalizumab | |
| 650 | 4 | |a Tacrolimus | |
| 650 | 4 | |a Vernal keratoconjunctivitis | |
| 650 | 7 | |a Cyclosporine |2 NLM | |
| 650 | 7 | |a 83HN0GTJ6D |2 NLM | |
| 650 | 7 | |a Ophthalmic Solutions |2 NLM | |
| 700 | 1 | |a Bielory, Leonard |e verfasserin |4 aut | |
| 700 | 1 | |a Dotchin, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Hamel, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Strube, Yi Ning J |e verfasserin |4 aut | |
| 700 | 1 | |a Koo, Euna B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Survey of ophthalmology |d 1956 |g 69(2024), 2 vom: 25. März, Seite 265-278 |w (DE-627)NLM000142956 |x 1879-3304 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2024 |g number:2 |g day:25 |g month:03 |g pages:265-278 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.survophthal.2023.10.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2024 |e 2 |b 25 |c 03 |h 265-278 | ||